Page 56 - HIV/AIDS Guidelines

52. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J
Med. Apr 26 2007;356(17):1723-1735.
53. Riddler SA, Li X, Otvos J, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among
HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. Jul 1 2008;48(3):281-288.
54. Ross AC, Armentrout R, O'Riordan MA, et al. Endothelial activation markers are linked to HIV status and are
independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr. Dec 15 2008;49(5):499-506.
55. McComsey G, Smith K, Patel P, et al. Similar reductions in markers of inflammation and endothelial activation after
initiation of abacavir/lamivudine or tenofovir/emtricitabine: The HEAT Study. Paper presented at 16th Conference on
Retroviruses and Opportunistic Infections (CROI): Feb. 8–11, 2009; Montreal, Canada.
56. Baker JV, Duprez D, Rapkin J, et al. Untreated HIV infection and large and small artery elasticity. J Acquir Immune
Defic Syndr. Sep 1 2009;52(1):25-31.
57. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a
randomized, treatment interruption trial. AIDS. May 15 2009;23(8):929-939.
58. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV
infection. PLoS Med. Oct 21 2008;5(10):e203.
59. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected
antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials
Group) Study 5152s. J Am Coll Cardiol. Aug 12 2008;52(7):569-576.

60. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med.
Nov 30 2006;355(22):2283-2296.

61. Marin B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination
antiretroviral therapy. AIDS. Aug 24 2009;23(13):1743-1753.

62. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. Nov 30
2008;22(18):2409-2418.

63. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining
malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir
Immune Defic Syndr. Jul 16 2009;52(2):203-205.
64. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and
antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet
Oncol. Oct 7 2009;10(12):1152-1159.
65. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-
AIDS-defining malignancies. AIDS. Oct 18 2008;22(16):2143-2153.
66. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired
immunodeficiency syndrome-defining malignancies. Cancer. Nov 15 2010;116(22):5306-5315.

67. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the
occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale
de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. Oct 1 2009;49(7):1109-1116.
68. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious
cause. AIDS. Nov 13 2009;23(17):2337-2345.
69. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with
immunosuppressed transplant recipients: a meta-analysis. Lancet. Jul 7 2007;370(9581):59-67.
70. Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a
strong predictor of AIDS-related lymphoma. J Infect Dis. Jul 1 2009;200(1):79-87.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents E-15

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.